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Abstract  
Introduction: Mild therapeutic hypothermia (33°C MTH) post out-of-hospital cardiac arrest 
(OHCA) is widely accepted as standard of care. However, uncertainty remains around the dose 
and therapy duration. OHCA patients are normally kept sedated +/- paralysed  and ventilated 
for the first 24 - 36 hours which allows for target temperature management (TTM), but makes 
neurological prognostication challenging. 
Objectives: The aim of this study is to investigate the feasibility and safety of assessing the 
unconscious OHCA patient after 12 hours for early waking / extubation whilst continuing to 
provide mild therapeutic hypothermia (MTH) for 24 hours, and fever prevention for 72 hours 
using an intravenous temperature management (IVTM) system and established conscious 
MTH anti-shiver regmens.  
Methods: This is a single centre, prospective, non-randomized observational study.  
A total of 50 consecutive unconscious survivors of OHCA, treated with MTH, who meet the 
THAW inclusion criteria will be enrolled. The patient will receive MTH using IVTM. After 
12 hours of MTH patients will be assessed using strict clinical criteria to determine suitability 
for early waking and extubation. Once awake and extubated MTH will continue for 24 hours 
with skin counter-warming and anti-shiver regimen followed fever prevention up to 72 hours. 
All patients will have serial electroencephalogram (EEG), somatic sensory potential (SSEP),  
and neuro-biomarkers performed on admission to ICU, 6 and 12 hours, then every 24 hours 
until 72 hours.  
Study End Points 
Primary - Patients successfully extubated whilst being treated with mild therapeutic 
hypothermia (33°C) following cardiac arrest. 
Secondary endpoints include – i) Length of ventilation support, ii) Neurological recovery at 
12 hours utilizing GCS, FOUR score and neurological assessment, iii) Assessment of Cerebral 
Performance Category (CPC) scale to indicate the patient’s neurological recovery on ICU and 
hospital discharge. iv) Length of ICU and hospital stay v) Re-intubation rate 
The study has been approved by the National Research Ethics Service, Health Research 
Authority. 
Background 
Out of hospital cardiac arrest (OHCA) – a global problem 
Cardiac arrest is a global problem affecting 50-100 per 100,000 in the general population, and 
ischaemic heart disease remains the leading cause of death in the western world (WHO, 2017; 
Deo et. Al., 2012).  Until recently neurologically intact survival following cardiac arrest had 
been very poor; however with improved early cardio-pulmonary resuscitation (CPR), better 
access to defibrillation and coronary revascularization as well as high quality intensive care 
support combined with targeted temperature management (TTM) survival rates have tripled in 
developed healthcare systems since 2001 (Wissenberg,  2013). 
 OHCA - Contemporary management 
When the aetiology of the cardiac arrest is assumed to be cardiac, in the majority of cases the 
patient will be taken to a heart attack centre (HAC) for consideration of revascularisation. 
Following the catheter lab, the patient is usually admitted to the Intensive Care Unit (ICU) 
where they will be sedated, paralysed, ventilated and receive Targeted Temperature 
Management (TTM) between 33-36°C. When the patient is normothermic, 24-36 hours later, 
sedation will be stopped to assess the patient’s neurological status and suitably appropriate 
patient’s would normally be extubated. When the patient no longer requires organ support they 
will be transferred to an appropriate step down cardiac care ward. 
Targeted temperature management (TTM)  
In 2013, the Targeted Temperature Management (TTM) trial showed no difference in clinical 
outcomes when comparing mild therapeutic hypothermia (MTH) at 33°C to maintaining a 
target temperature of 36°C (Nielsen et. Al., 2013).  
However, MTH remains within the current guidance for the management of OHCA survivors 
as outlined by all major international resuscitation committees (RCUK, 2015; ERC and 
ESICM, 2015; ANZCOR, 2016; ILCOR, 2015; AHA, 2015). Furthermore, MTH was endorsed 
by the Cochrane report (2016) and the UK National Institute for Health and Care Excellence 
(NICE, 2011). Further hypotheses regarding the clinical utility of MTH will be tested in the 
upcoming TTM2 trial due to start towards the end of 2017.  
Brain injury and neurological assessments 
Brain injury is the most common cause of morbidity and mortality in patients with a return of 
spontaneous circulation who are subsequently admitted to hospital (Nichol et. al, 1999; Burke 
et al., 2005).  
Prognostication in the unconscious cardiac arrest survivor is difficult. Patients are initially 
sedated and paralysed, usually for a minimum of 24 hours and only after they are re-warmed 
to normothermia is neuro-prognostication attempted. Without advanced multi-modal 
neurological testing and access to neurology and neuro-electrophysiology services, many 
cardiac centres rely on basic neurological clinical assessment. 
The electroencephalogram (EEG) and somatosensory evoked potential (SSEP) are both 
thought to be useful to predict poor outcome. EEG is also helpful to assess level of 
consciousness as well as detecting non-convulsive seizures, which can then be treated. An 
isoelectric EEG at 72 hours is associated with poor outcome (Zanderbergen et. al., 2006).  
SSEP has also been described as a useful bedside tool, which is not affected by sedation, 
paralysis (unless high doses administered) or MTH and is able to assess periphery, brainstem 
and cortical function (Rothstein, 2014). Upper Limb SSEP is obtained through stimulation of 
the median nerve at the wrist and recording the N20 cortical response. A bilateral absence of 
N20 at 24 hours has shown to predict poor outcome (Sandroni and Geocadin, 2015).18  
Another useful predictor of neurological outcome is brain derived proteins, neuron-specific 
enolase (NSE) and S-100B. It has recently been described that serum concentrations of both 
these neuro-proteins peak within the first 24 hours in patients with a favourable to moderate 
neurological outcome, but continue to rise up to 3 days after cardiac arrest in patients with 
unfavourable outcomes (Pfeifer et al., 2014).  
The problem – TTM and sedation / paralysis and ability to prognosticate 
When the patient is in an induced coma, and receiving TTM / MTH clinicians have a limited 
ability to assess a patient’s neurological function, making prognostication difficult. 
Furthermore, diagnosis and treatment of neurological complications such as non-convulsive 
seizures are difficult to detect when relying just on clinical assessment.  
Conscious therapeutic hypothermia  
Providing MTH in conscious patients has been demonstrated to be both feasible and safe,  
providing skin counter-warming and a rigorous anti-shivering regimen is concurrently 
employed (Georgia et. al., 2004; Lyden et. al., 2014; Dixon et. al., 2002; Erlinge et al, 2014; 
Götberg et. al., 2010).  
At the Essex Cardiothoracic Centre (ECTC) we have considerable experience in conscious 
induction and management of MTH within the COOL-AMI Case series, and COOL AMI EU 
pilot study.25 26 In these studies conscious patients who presented with ST-elevation myocardial 
infarction (STEMI) were cooled to 32°C with an intravascular device inserted via the femoral 
vein into the inferior vena cava, while administering a rigorous anti-shivering strategy.  
Purpose of Therapeutic Hypothermia and eArly Waking (THAW) study 
The purpose of the THAW study is to assess the safety and feasibility of stopping sedation at 
12 hours, whilst continuing to provide mild therapeutic hypothermia (33°C). This will allow 
clinicians to perform an earlier neurological assessment and discontinue mechanical ventilation 
as soon as practicable, whilst still allowing the patient potential benefit from MTH.  
To ensure only appropriate patients are selected for early waking, patients will be assessed on 
their cardiovascular, respiratory and neurological stability. Patients who are considered 
clinically stable will be commenced on a rigorous anti-shivering regime, which allows for the 
continuation of therapeutic hypothermia with minimal or no discomfort to the patient. Sedation 
can then be stopped to enable the clinician to perform a comprehensive neurological 
assessment with the view to extubating suitably appropriate patients early.  
The hypothesis is that THAW trial protocol will allow clinicians to prognosticate much earlier, 
with an emphasis on positive prognostication. Administration of sedation is minimised as well 
as reduction in mechanical ventilation, therefore potentially reducing intensive care and 
hospital length of stay.  
Study Design 
This is a single centre, prospective, non-randomized, safety and feasibility study.  All 
unconscious patients who have had a return of spontaneous circulation (ROSC) after an OHCA 
following admission to the Essex Cardiothoracic Centre (ECTC) and are planned for MTH 
treatment are eligible for the study. Patients fulfilling inclusion criteria and no exclusion criteria 
will be enrolled. (Table 1)  
50 patients will be recruited to this study, which we have judged to be appropriate to assess the 
feasibility and safety of the intervention, results being compared to a consecutive 50 patient 
historical cohort. 
Table 1  - THAW Inclusion and exclusion criteria: 
 
Methods / Study Intervention 
Enrolled patients will have an Icy® catheter (Zoll Inc, USA) inserted into the femoral vein and 
intra-venous temperature management (IVTM) will be initiated in the catheter lab i.e. 
immediately prior to or following coronary imaging / revascularization. The target temperature 
is set to 33°C, which will continue for 24 hours from the time the patient reaches target 
temperature. The patient will be transferred to the ICU where physiological observations will 
be continuously monitored and organs supported as required. Regular neurological assessment 
utilising Glasgow Coma Scale (GCS) and FOUR scoring will be performed and sedatives 
administered to achieve a Richmond Agitation-Sedation Scale of -3 to -5. Depending on 
clinical stability and any evidence of shivering, preference is given to bolus administration of 
paralysing agents as opposed to a continuous infusion. Figure 1 outlines the THAW 
intervention protocol. 
Between 11-12 hours from admission to the ICU a comprehensive cardiovascular, respiratory 
and neurological assessment is performed to identify patients that might be suitable for early 
waking. This requires the patient to be cardiovascularly stable, on minimal or no inotropic 
support; normal gas exchange, requiring less than 50% oxygen and no evidence of adverse 
neurological signs. Providing these criteria are met the patient would be considered appropriate 
for early waking and started on a rigorous anti-shivering regime (Table 2). The patient is 
continuously assessed for extubation against established criteria (Table 3) 
Table 2 – THAW anti-shiver guideline
 
  
Table 3 – THAW early Extubation Criteria 
 
Figure 1 The early waking and neurological prognostication protocolStudy End Points 
 
Primary 
Patients successfully extubated whilst being treated with mild therapeutic hypothermia (33°C) 
following cardiac arrest. 
Secondary 
1. Length of ventilation support 
2. Neurological recovery at 12 hours utilizing GCS, FOUR score and neurological 
assessment. 
3. Assessment of Cerebral Performance Category (CPC) scale to indicate the patient’s 
neurological recovery on ICU and hospital discharge. 
4. Length of ICU and hospital stay 
5. Re-intubation rate 
Statistical analysis 
Continuous variables will be presented as mean ± standard deviation (SD), and categorical 
variables will be presented as absolute numbers and/or percentages.  
A Shapiro-Wilks test will be performed to assess the normality of the variables investigated.  
According to this, an ANOVA analysis or a Mann-Whitney test will be used, where 
appropriate, for univariate analysis.  For categorical variables will be used a McNemar test. 
Survival analysis will be performed using Kaplan-Meier’s method.  
A Wilcoxon signed-rank post-hoc test or a paired sample t-test will be used to assess statistically 
significant differences in the measured parameters within different selected times. For all tests, a p-
value <0.05 will be considered statistically significant.  
The SPSS software, version 23.0 (IBM Corporation, Armonk, New York), will be used for 
statistical analysis.  
Discussion 
The THAW trial will investigate whether unconscious survivors of cardiac arrest can be 
successfully weaned from sedation and ventilation after 12 hours whilst continuing to receive 
MTH for 24 hours and temperature management to prevent fever for 72 hours. It also allows 
the clinician to perform a comprehensive neurological assessment using a multimodal approach 
and neuro-prognosticate after 12 hours.  
The THAW protocol makes this feasible by utilising IVTM to achieve core temperature 
management, combined with a rigorous anti-shiver regime including a heated surface counter-
warming air blanket, as well as oral Buspirone and intravenous Pethidine. This combination 
prevents or minimises the patient from shivering and experiencing discomfort. 
Within the THAW protocol we have also incorporated a multimodal approach to assess 
neurological function. Early serial neuro-electrophysiology (EEG and SSEP), as well as 
biomarkers S100b and NSE have been measured on all patients at admission, 6, 12 hours, then 
every 24 hours for the first 72 hours or until the patient regains consciousness.  
Whilst neuro-electrophysiology and biomarkers have been incorporated into the THAW trial 
interventions, these will retrospectively be analysed and interpreted by experts at a core lab 
offsite who will describe the quality of the recordings for diagnostic purposes, as well as 
interpret the findings. The analysis of these results will be compared to the clinical outcome of 
the patient at the completion of the trial, and will not be available to influence the clinical 
decision to wake the patient early, instead this will be determined by a strict criteria and clinical 
suitability as previously described. Once recruitment is complete we will determine if any of 
the early neuro-electrophysiology and biomarkers are helpful to predict suitable patients for 
early waking and a positive neurological outcome. 
This study has a number of  limitations. Firstly it is only a single centre trial, and one which 
has vast experience in providing MTH to conscious patients, therefore any safety and feasibility 
conclusions may not be extrapolated to other real world practice. The sample size is relatively 
small and there is no randomized control group instead just a consecutive historical control 
group. We do however believe that for the purposes of proving feasibility and safety in this 
cohort the numbers are adequate. 
Conclusion 
A trial of early waking and prognostication in OHCA has never been performed. In this single 
centre study we aim to wake suitably appropriate patients early, after 12 hours whilst 
continuing to provide MTH for 24 hours. For this group of patients it may allow clinicians to 
perform a much more comprehensive neurological assessment earlier, with an emphasis on 
positive neurological-prognostication. It also provides an opportunity to identify suitable 
patients who meet established criteria to be extubated early, therefore reducing mechanical 
ventilation time. The ability to continue temperature management in the conscious patient 
using IVTM, allows fever prevention for up to 72 hours with a concurrent rigorous anti-shiver 
regime, ensuring patient comfort. The hypothesis being patients who are extubated and no 
longer require multiple organ support can then be discharged from ICU, whilst continuing to 
receive IVTM for fever prevention, and transferred to a high dependency or ward environment, 
reducing the ICU length of stay, enhancing the patient’s recovery and potentially reducing their 
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